Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Preferred Shares (2023 - 2025)

Historic Preferred Shares for Spyre Therapeutics (SYRE) over the last 3 years, with Q3 2025 value amounting to $146.4 million.

  • Spyre Therapeutics' Preferred Shares changed 0.0% to $146.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $146.4 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $146.4 million for FY2024, which is 2082.01% down from last year.
  • Latest data reveals that Spyre Therapeutics reported Preferred Shares of $146.4 million as of Q3 2025, which was down 0.0% from $146.4 million recorded in Q2 2025.
  • In the past 5 years, Spyre Therapeutics' Preferred Shares registered a high of $184.9 million during Q4 2023, and its lowest value of $146.4 million during Q2 2024.
  • Moreover, its 3-year median value for Preferred Shares was $146.4 million (2024), whereas its average is $156.1 million.
  • In the last 5 years, Spyre Therapeutics' Preferred Shares tumbled by 2082.01% in 2024 and then changed by 0.0% in 2025.
  • Spyre Therapeutics' Preferred Shares (Quarter) stood at $184.9 million in 2023, then fell by 20.82% to $146.4 million in 2024, then changed by 0.0% to $146.4 million in 2025.
  • Its Preferred Shares stands at $146.4 million for Q3 2025, versus $146.4 million for Q2 2025 and $146.4 million for Q1 2025.